DK1011733T3 - Sammensætninger og fremgangsmåder til at forbedre levering af terapeutiske midler til celler - Google Patents

Sammensætninger og fremgangsmåder til at forbedre levering af terapeutiske midler til celler

Info

Publication number
DK1011733T3
DK1011733T3 DK98934359T DK98934359T DK1011733T3 DK 1011733 T3 DK1011733 T3 DK 1011733T3 DK 98934359 T DK98934359 T DK 98934359T DK 98934359 T DK98934359 T DK 98934359T DK 1011733 T3 DK1011733 T3 DK 1011733T3
Authority
DK
Denmark
Prior art keywords
compositions
cells
methods
therapeutic agents
improve delivery
Prior art date
Application number
DK98934359T
Other languages
English (en)
Inventor
Heidrun Engler
Tattanahalli L Nagabhushan
Stephen Kenneth Youngster
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Application granted granted Critical
Publication of DK1011733T3 publication Critical patent/DK1011733T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK98934359T 1997-07-08 1998-07-08 Sammensætninger og fremgangsmåder til at forbedre levering af terapeutiske midler til celler DK1011733T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/889,355 US7002027B1 (en) 1996-01-08 1997-07-08 Compositions and methods for therapeutic use
PCT/US1998/014241 WO1999002191A1 (en) 1997-07-08 1998-07-08 Compositions and methods for enhancing delivery of therapeutic agents to cells

Publications (1)

Publication Number Publication Date
DK1011733T3 true DK1011733T3 (da) 2009-09-28

Family

ID=25394956

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98934359T DK1011733T3 (da) 1997-07-08 1998-07-08 Sammensætninger og fremgangsmåder til at forbedre levering af terapeutiske midler til celler

Country Status (21)

Country Link
US (3) US7002027B1 (da)
EP (2) EP1011733B1 (da)
JP (2) JP4460148B2 (da)
KR (1) KR100691572B1 (da)
AR (1) AR016312A1 (da)
AT (2) ATE434448T1 (da)
AU (1) AU774338B2 (da)
CA (1) CA2294709C (da)
CY (1) CY1109367T1 (da)
DE (2) DE69840932D1 (da)
DK (1) DK1011733T3 (da)
ES (2) ES2362027T3 (da)
HK (2) HK1028961A1 (da)
HU (1) HUP0002683A3 (da)
IL (1) IL133929A0 (da)
MY (1) MY138257A (da)
NZ (1) NZ502060A (da)
PT (1) PT1011733E (da)
TW (1) TW490306B (da)
WO (1) WO1999002191A1 (da)
ZA (1) ZA986003B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
EP1070047A2 (en) 1998-04-08 2001-01-24 Celltech Chiroscience Limited Lipids
AU2002366809A1 (en) * 2001-12-20 2003-07-09 Schering-Plough Corporation Syn3 compositions and methods
CN100429220C (zh) * 2003-06-04 2008-10-29 坎基股份有限公司 用于干扰素治疗的方法和组合物
CA2527658A1 (en) * 2003-06-04 2004-12-16 Canji, Inc. Methods and compositions for interferon therapy
US7790039B2 (en) * 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
WO2005058368A1 (en) * 2003-12-10 2005-06-30 Canji, Inc. Methods and compositions for treatment of interferon-resistant tumors
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
WO2007030588A1 (en) * 2005-09-07 2007-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
WO2009136396A2 (en) * 2008-05-05 2009-11-12 Tiltan Pharma Ltd. Sulfobetaines for therapy
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
EP4089169A1 (en) 2009-10-12 2022-11-16 Larry J. Smith Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
US20120147800A1 (en) * 2010-12-10 2012-06-14 Minyoung Park Power management in a wireless network having stations with different power capabilities
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
US10492104B2 (en) * 2016-03-10 2019-11-26 Cable Television Laboratories, Inc. Latency reduction in wireless service

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554386A (en) 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6207454B1 (en) 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5120316A (en) 1990-09-28 1992-06-09 Akzo N.V. Urethral catheter and catheterization process
JPH07500961A (ja) 1990-10-01 1995-02-02 ユニバーシティ オブ コネチカット 細胞による選択的内在化を目的としたウイルス及び細胞の標的設定
DE59108326D1 (de) * 1990-12-06 1996-12-12 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindung als Arzneimittel
JPH06509329A (ja) 1991-06-28 1994-10-20 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 細胞の部位特異的な点滴注入または細胞の部位特異的形質転換による疾患の治療およびそのためのキット
WO1993002556A1 (en) 1991-07-26 1993-02-18 University Of Rochester Cancer therapy utilizing malignant cells
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5602023A (en) 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
ATE260679T1 (de) 1992-04-03 2004-03-15 Univ California Selbstorganisierendes system zur verabreichung von polynukleotiden enthaltend ein amphiphatisches peptid
CA2133411A1 (en) 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US5656609A (en) 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
WO1994006923A1 (en) 1992-09-24 1994-03-31 The University Of Connecticut Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
JPH07109983A (ja) 1993-10-13 1995-04-25 Nippondenso Co Ltd スクロール型圧縮機
AU8076494A (en) 1993-10-15 1995-05-04 Cytrx Corporation Therapeutic delivery compositions and methods of use thereof
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5552309A (en) 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
WO1997005209A1 (en) * 1995-07-28 1997-02-13 Kohne David E Method for enhancing chemiluminescence
US20040014709A1 (en) 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US5671110A (en) 1996-01-23 1997-09-23 Oneac Corporation Ground skew protection method and apparatus
US6283940B1 (en) * 1997-08-29 2001-09-04 S. Grant Mulholland Catheter
US6938069B1 (en) * 2000-03-18 2005-08-30 Computing Services Support Solutions Electronic meeting center
AU2002366809A1 (en) 2001-12-20 2003-07-09 Schering-Plough Corporation Syn3 compositions and methods
KR100499787B1 (ko) 2002-11-29 2005-07-07 인티그런트 테크놀로지즈(주) 스위치 모드 동작을 하는 선형성이 우수한 광대역 가변이득 증폭기
CN100429220C (zh) 2003-06-04 2008-10-29 坎基股份有限公司 用于干扰素治疗的方法和组合物
CA2527658A1 (en) 2003-06-04 2004-12-16 Canji, Inc. Methods and compositions for interferon therapy
WO2004108898A2 (en) 2003-06-04 2004-12-16 Canji, Inc. Transfection agents
WO2005058368A1 (en) 2003-12-10 2005-06-30 Canji, Inc. Methods and compositions for treatment of interferon-resistant tumors

Also Published As

Publication number Publication date
HK1134025A1 (en) 2010-04-16
US8022044B2 (en) 2011-09-20
EP1011733A4 (en) 2004-09-29
JP4460148B2 (ja) 2010-05-12
EP2106807B1 (en) 2011-02-09
US20060199782A1 (en) 2006-09-07
HUP0002683A2 (hu) 2000-12-28
DE69842133D1 (de) 2011-03-24
JP2010070565A (ja) 2010-04-02
US7538093B2 (en) 2009-05-26
HK1028961A1 (en) 2001-03-16
AU8390198A (en) 1999-02-08
CA2294709A1 (en) 1999-01-21
DE69840932D1 (de) 2009-08-06
NZ502060A (en) 2003-01-31
KR100691572B1 (ko) 2007-03-12
EP1011733B1 (en) 2009-06-24
US7002027B1 (en) 2006-02-21
KR20010021620A (ko) 2001-03-15
ES2362027T3 (es) 2011-06-27
CA2294709C (en) 2010-05-11
AU774338B2 (en) 2004-06-24
ATE434448T1 (de) 2009-07-15
CY1109367T1 (el) 2014-07-02
ES2328094T3 (es) 2009-11-06
JP2001509492A (ja) 2001-07-24
MY138257A (en) 2009-05-29
PT1011733E (pt) 2009-09-15
EP1011733A1 (en) 2000-06-28
HUP0002683A3 (en) 2005-09-28
US20100028431A1 (en) 2010-02-04
WO1999002191A1 (en) 1999-01-21
TW490306B (en) 2002-06-11
ATE497786T1 (de) 2011-02-15
ZA986003B (en) 1999-01-28
AR016312A1 (es) 2001-07-04
EP2106807A1 (en) 2009-10-07
IL133929A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
DK1011733T3 (da) Sammensætninger og fremgangsmåder til at forbedre levering af terapeutiske midler til celler
DK1148875T3 (da) Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer
NO973046L (no) Elastiske brönnsementsammensetninger og fremgangsmåter
NO973048L (no) Elastiske brönnsementsammensetninger og fremgangsmåter
DK1021410T3 (da) Prostaglandinagonister og deres anvendelse til behandling af knogletilstande
ID25824A (id) Formulasi terapeutik untuk memberikan tolterodin dengan pelepasan yang terkendali
NO964583D0 (no) Lettvekts brönnsementsammensetninger og fremgangsmåter
DK0969846T4 (da) Sammensætninger og fremgangsmåder til reduktion af okulær hypertension
DK0971735T3 (da) Fremgangsmåder og præparater til behandling af inflammatorisk tarmsygdom
NO20004540L (no) Sammensetninger av peptider, formuleringer og anvendelse derav
DE69924589D1 (de) Einphasige Silikon- und Wasserzusammensetzung
NO994506D0 (no) FremgangsmÕter og blandinger for Õ modulere mottagelighet for kortikosteroider
DK0948349T3 (da) In vitro-fremgangsmåder og anvendelse af farmaceutiske præparater til behandling af indre øre-hårceller
NO20022334L (no) Ny sammensetning og anvendelse
NO20005100D0 (no) Genetisk modifiserte celler og fremgangsmÕter for ekspresjon av rekombinant heparanase og fremgangsmÕter for rensing av samme
ID19470A (id) Komposisi bahan pembangkit gas
ID24610A (id) Radas serta metode untuk mengkristalisasian
DE69828474D1 (de) Kühlung von rotorschaufeln in gasturbinen
NO995222D0 (no) Forbedringer i og vedrörende gassgeneratorer
ID23429A (id) Komposisi-komposisi sertralina yang larut
NO973047D0 (no) Elastiske sementsammensetninger og fremgangsmåter
IS5931A (is) Notkun smáveiruhjúphluta til að hamla frumufjölgun og frumuflutningi
FI974235A0 (fi) Ny bestaemningsmetod
DK1100771T3 (da) Forbindelser og sammensætninger til levering af aktive midler
SE9704170D0 (sv) Directed cytolysis of target cells, agents and compositions causing cytolysis, and compounds that can be used to produce the agents